

Message

---

**From:** stepp.cathy@epa.gov [stepp.cathy@epa.gov]  
**Sent:** 3/29/2019 6:53:30 PM  
**To:** Furey, Eileen [furey.eileen@epa.gov]  
**CC:** Newton, Cheryl [Newton.Cheryl@epa.gov]; Thiede, Kurt [thiede.kurt@epa.gov]; Nam, Ed [nam.ed@epa.gov]; Kelley, Jeff [kelley.jeff@epa.gov]  
**Subject:** Re: Pre-release of Willowbrook Study

Thanks

Sent from my iPhone

On Mar 29, 2019, at 1:40 PM, Furey, Eileen <[furey.eileen@epa.gov](mailto:furey.eileen@epa.gov)> wrote:

Here's another "Results" summary that appears at the beginning of the report. We're just starting to read the whole thing.

**Results:** Significantly elevated Hodgkin's lymphoma cases in females were observed in study area 1 as compared to county (SIR 1.86, CI 1.12-2.91) and state averages (SIR 1.89, CI 1.14-2.95). Female breast cancer was elevated in both study areas when compared to the state average (Study Area 1: SIR 1.10, CI 1.02-1.18; Study Area 2: SIR 1.07, CI 1.02-1.13). The elevation, however, became non-significant when compared to the county average. Trends in SIR's showed a monotonic increase with time in female non-Hodgkin's lymphoma, with the SIR becoming statistically significant in the most recent time period, 2009-2015 (Study Area 1: SIR 1.61, CI 1.19-2.21; Study Area 2: SIR 1.33, CI 1.07-1.63). Pediatric lymphoma was observed to be elevated over the entire study period in females of both study areas. Other adult cancer sites observed to be elevated include prostate cancer, and female pancreatic, ovarian, and bladder cancers. Also, female leukemia was found to be significantly lower than expected, and lung cancer seemed to be lower in both males and females.

**Conclusions:** The study's results, when taken as a whole, indicated that some cancers were elevated in populations living near the Sterigenics facility in Willowbrook, Illinois. Many apparent differences and inconsistencies, however, existed between genders, across study areas, and among cancer sites. Further studies, preferably with larger populations and multiple facilities, are strongly recommended to confirm this assessment's findings.

Eileen L. Furey  
Deputy Director  
Air and Radiation Division  
U.S. EPA Region 5  
(312) 886-7950

---

**From:** Furey, Eileen  
**Sent:** Friday, March 29, 2019 1:36 PM  
**To:** Newton, Cheryl <[Newton.Cheryl@epa.gov](mailto:Newton.Cheryl@epa.gov)>; Thiede, Kurt <[thiede.kurt@epa.gov](mailto:thiede.kurt@epa.gov)>; Stepp, Cathy <[stepp.cathy@epa.gov](mailto:stepp.cathy@epa.gov)>  
**Cc:** Nam, Ed <[nam.ed@epa.gov](mailto:nam.ed@epa.gov)>; Kelley, Jeff <[kelley.jeff@epa.gov](mailto:kelley.jeff@epa.gov)>  
**Subject:** FW: Pre-release of Willowbrook Study

We just received this pre-release – looking at it now. The “Results” conclusion ends up with the following:

In conclusion, this cancer assessment examined a number of cancer sites that included cancers that have a recognized association with EtO (lymphohematopoietic and breast cancers), and other common cancer sites that have no such association with EtO, in both adult and pediatric surrounding the Sterigenics facility in Willowbrook, Illinois, over the years 1995 through 2015. For lymphohematopoietic and breast cancers the study found increases in Hodgkin’s lymphoma, and in recent years, non-Hodgkin’s lymphoma. Pediatric lymphoma was also elevated during the study period. For other common cancer sites, the study found increased cancer in prostate for males, and increased cancers of the pancreas, ovary, and bladder in females. However, many apparent differences and inconsistencies existed between genders, across study areas, and among cancer sites. A number of limitations in methodology and data also exist. Future studies with larger populations and preferably involving multiple EtO emissions sites are strongly recommended to confirm this assessment’s findings.

Eileen L. Furey  
Deputy Director  
Air and Radiation Division  
U.S. EPA Region 5  
(312) 886-7950

---

**From:** Siegel, Kathryn  
**Sent:** Friday, March 29, 2019 1:24 PM  
**To:** Cain, Alexis <[cain.alexis@epa.gov](mailto:cain.alexis@epa.gov)>; Furey, Eileen <[furey.eileen@epa.gov](mailto:furey.eileen@epa.gov)>; Nam, Ed <[nam.ed@epa.gov](mailto:nam.ed@epa.gov)>; Kelley, Jeff <[kelly.jeff@epa.gov](mailto:kelly.jeff@epa.gov)>  
**Subject:** Fwd: Pre-release of Willowbrook Study

Just in case you weren’t blind copied

Sent from my iPhone

Begin forwarded message:

**From:** "Florian, Nick" <[Nick.Florian@illinois.gov](mailto:Nick.Florian@illinois.gov)>  
**To:** "Florian, Nick" <[Nick.Florian@illinois.gov](mailto:Nick.Florian@illinois.gov)>  
**Subject:** Pre-release of Willowbrook Study

Please see the attached copy of the pre-release of the study; which is embargoed for 1 hour. The press release and full public release of the report will follow this afternoon at 2pm.

Thank you,

Nick

Nick Florian  
Division Chief, Governmental Affairs  
Office: 217-782-6188  
Cell: 217-280-3285

State of Illinois - CONFIDENTIALITY NOTICE: The information contained in this communication is confidential, may be attorney-client privileged or attorney work product, may constitute inside information or internal deliberative staff communication, and is intended only for the use of the addressee. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify the sender immediately by return e-mail and destroy this communication and all copies thereof, including all attachments. Receipt by an unintended recipient does not waive attorney-client privilege, attorney work product privilege, or any other exemption from disclosure.